CMOD方案治疗老年初治非特殊型外周T细胞淋巴瘤的临床疗效和安全性评价  

Clinical Efficacy and Safety of CMOD Regimen as the First Treatment for Aged New-diagnosed Patients with Peripheral T-cell Lymphoma

作　　者：刘晓蕾[1] 高磊[1] 崔娜[1] 

机构地区：[1]保定市第一中心医院血液内科,河北保定071000

出　　处：《中国实验血液学杂志》2017年第3期791-795,共5页Journal of Experimental Hematology

摘　　要：目的:探讨CMOD方案一线治疗老年初治非特殊型外周T细胞淋巴瘤(PTCL)的临床疗效和安全性。方法:选取2014年3月至2015年3月收治的76例经病理确诊的非特殊型外周T细胞淋巴瘤患者给予CMOD方案治疗(CMOD组,38例)和CHOP常规化疗方案治疗(CMOP组,38例)。比较2组患者的近期临床疗效、无进展生存期和总生存时间以及2组患者治疗过程中的不良反应发生情况。结果:CMOD组总有效率65.79%,CHOP组总有效率60.53%(P>0.05)。2组的化疗不良反应包括有骨髓抑制、黏膜炎、胃肠道反应、发热、肝功能损害、神经毒性、脱发等,其中CMOD组脱发及Ⅲ、Ⅳ级粒细胞下降的发生率(34.21%、13.16%)均明显低于CHOP组(84.21%、34.21%)(P<0.05)。CMOD组无进展生存期及总生存期(10.98±2.23个月、14.43±2.48个月)均明显高于CHOP组(8.31±2.62个月、10.93±2.07个月)(P<0.05)。结论:CMOD方案治疗老年初治非特殊型外周T细胞淋巴瘤患者的近期临床疗效与CHOP方案相当,但可在一定程度上能延长患者无病生存期和总生存期并降低脱发和粒细胞下降的发生率。Objective： To investigate clinical efficacy and safety of CMOD regimen as the first treatment for the aged new-diagnosed patients with peripheral T-cell lymphoma. Methods： Seventy-six patients diagnosed as peripheral T cell lymphoma according to chemotherapy were divided into the 2 group： A and B groups. The patients in A group received CMOD regimen （38 cases） and the patients in B group received CHOP regiment （38 cases）. The clinical efficacy, PFS （progression-free survival）, OS and the adverse reactions in the 2 groups were compared. Results： The total effeciency rate was not statistically different between CMOD（64.52% ）and CHOP groups （58.06%） （P 〉 0.05 ）. The adverse reactions in 2 groups were as follows： myelosuppression, mucositis, gastrointestinal reactions, fever, liver dysfunction, neurotoxicity, and alopecia etc. The incidence of alopecia and the grade Ⅲand IV of neutropenia in the CMOD group （34. 21%, 13. 16% ） were statistically significantly lower than those in the CHOP group （84.21%, 34. 21% ） （P 〈0.05）. The progression-free survival and 1-year overall survival of observation group （ 10.98 ± 2.23 months, 14.43 ± 2.48 months） were significantly higher than those in the CHOP group（8.31±2.62 months, 10.93 ± 2.07 months） （ P 〈 0.05 ）. Conclusion： The clinical efficacy of CMOD regimen has been confirmed to be equivalent with CHOP regimen for the aged new-diagnosed patients with peripheral T-cell lymphoma. This regimen can prolong the progression-free survival and overall survival to some extent and reduce the incidence of hair loss and neutropenia, which may be applied to the clinical practice.

关 键 词：非特殊型外周T细胞淋巴瘤 CMOD方案 CHOP方案 

分 类 号：R733.1[医药卫生—肿瘤]